Loading...

APC anti-mouse CD25 Antibody

Pricing & Availability
Clone
PC61 (See other available formats)
Regulatory Status
RUO
Other Names
IL-2Rα, Ly-43, p55, Tac
Isotype
Rat IgG1, λ
Ave. Rating
Submit a Review
Product Citations
publications
pc61
Con A-stimulated (3 days)splenocytes stained with PC61 APC
  • pc61
    Con A-stimulated (3 days)splenocytes stained with PC61 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
102011 25 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102012 100 µg 125€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD25 is a 55 kD glycoprotein also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Application References

(PubMed link indicates BioLegend citation)
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  2. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  3. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  4. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
  5. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  6. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  7. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  8. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  9. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  10. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  11. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  12. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  13. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  14. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  15. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  16. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  17. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  18. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  19. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  20. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
  21. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  22. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  23. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  24. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
  25. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
  26. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  27. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  28. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  29. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  30. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
  31. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  32. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
  33. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  34. Shi L, et al. 2021. Immunity. . PubMed
  35. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
  36. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
  37. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
  38. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
  39. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  40. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  41. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  42. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  43. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  44. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  45. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  46. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  47. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  48. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  49. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  50. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  51. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  52. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  53. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  54. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  55. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
  56. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  57. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  58. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  59. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  60. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
  61. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  62. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  63. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  64. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  65. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
  66. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  67. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
  68. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  69. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
  70. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  71. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  72. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  73. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  74. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  75. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  76. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  77. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  78. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  79. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  80. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  81. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  82. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  83. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  84. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  85. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  86. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  87. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  88. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  89. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  90. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
  91. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  92. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  93. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
  94. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  95. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  96. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  97. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  98. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  99. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  100. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  101. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  102. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  103. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  104. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  105. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  106. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  107. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  108. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
  109. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  110. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  111. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
RRID
AB_312860 (BioLegend Cat. No. 102011)
AB_312861 (BioLegend Cat. No. 102012)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD25 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD25 PC61 FC
Biotin anti-mouse CD25 PC61 FC
FITC anti-mouse CD25 PC61 FC
PE anti-mouse CD25 PC61 FC
PE/Cyanine5 anti-mouse CD25 PC61 FC
Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
PE/Cyanine7 anti-mouse CD25 PC61 FC
Alexa Fluor® 488 anti-mouse CD25 PC61 FC
Alexa Fluor® 647 anti-mouse CD25 PC61 FC
Pacific Blue™ anti-mouse CD25 PC61 FC
Alexa Fluor® 700 anti-mouse CD25 PC61 FC
APC/Cyanine7 anti-mouse CD25 PC61 FC
PerCP/Cyanine5.5 anti-mouse CD25 PC61 FC
PerCP anti-mouse CD25 PC61 FC
Brilliant Violet 421™ anti-mouse CD25 PC61 FC
Brilliant Violet 605™ anti-mouse CD25 PC61 FC
Brilliant Violet 650™ anti-mouse CD25 PC61 FC
Ultra-LEAF™ Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Brilliant Violet 510™ anti-mouse CD25 PC61 FC
PE/Dazzle™ 594 anti-mouse CD25 PC61 FC
Brilliant Violet 711™ anti-mouse CD25 PC61 FC
Brilliant Violet 785™ anti-mouse CD25 PC61 FC
Alexa Fluor® 594 anti-mouse CD25 PC61 IHC-F
APC/Fire™ 750 anti-mouse CD25 PC61 FC
TotalSeq™-A0097 anti-mouse CD25 PC61 PG
KIRAVIA Blue 520™ anti-mouse CD25 PC61 FC
TotalSeq™-B0097 anti-mouse CD25 PC61 PG
TotalSeq™-C0097 anti-mouse CD25 PC61 PG
Spark NIR™ 685 anti-mouse CD25 Antibody PC61 FC
PE/Fire™ 640 anti-mouse CD25 PC61 FC
Spark YG™ 581 anti-mouse CD25 PC61 FC
APC/Fire™ 810 anti-mouse CD25 PC61 FC
Brilliant Violet 750™ anti-mouse CD25 PC61 FC
PerCP/Fire™ 780 anti-mouse CD25 PC61 FC
PE/Fire™ 700 anti-mouse CD25 PC61 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account